![Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline | Journal of Nuclear Medicine Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/52/1/81/F1.large.jpg)
Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline | Journal of Nuclear Medicine
![18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer](https://www.spandidos-publications.com/article_images/ol/11/1/ol-11-01-0316-g00.jpg)
18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer
![18 F-FCH PET/CT in a 58-year-old prostate cancer patient, Gleason score... | Download Scientific Diagram 18 F-FCH PET/CT in a 58-year-old prostate cancer patient, Gleason score... | Download Scientific Diagram](https://www.researchgate.net/profile/Mohsen-Beheshti-2/publication/276359816/figure/fig1/AS:427305894977537@1478889072574/18-F-FCH-PET-CT-in-a-58-year-old-prostate-cancer-patient-Gleason-score-7-PSA-223.png)
18 F-FCH PET/CT in a 58-year-old prostate cancer patient, Gleason score... | Download Scientific Diagram
![PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases | Imaging Technology News PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases | Imaging Technology News](https://www.itnonline.com/sites/default/files/styles/content_large/public/LOCATETrialPETCTSuspectedRecurrentProstateCancer.jpg?itok=CmS11TwR)
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases | Imaging Technology News
![PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework - ScienceDirect PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2214442018303577-egi10LGC7V9QWW.jpg)
PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework - ScienceDirect
![Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study | BMC Cancer | Full Text Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-07192-7/MediaObjects/12885_2020_7192_Fig2_HTML.png)
Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study | BMC Cancer | Full Text
![Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease - Practical Radiation Oncology Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease - Practical Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2118910396/2086592317/gr1.jpg)